JP2000506835A - 治療用の修飾サイトカイン - Google Patents

治療用の修飾サイトカイン

Info

Publication number
JP2000506835A
JP2000506835A JP9530545A JP53054597A JP2000506835A JP 2000506835 A JP2000506835 A JP 2000506835A JP 9530545 A JP9530545 A JP 9530545A JP 53054597 A JP53054597 A JP 53054597A JP 2000506835 A JP2000506835 A JP 2000506835A
Authority
JP
Japan
Prior art keywords
tnf
ligand
cells
necrosis factor
tumor necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9530545A
Other languages
English (en)
Japanese (ja)
Inventor
コルティ，アンジェロ
シッカルディ，アントニオ
デッラボナ，パオロ
カソラティ，ジウリア
ペラジ，ミカエラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAN RAFFAELE CENTRO FOND
Original Assignee
SAN RAFFAELE CENTRO FOND
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAN RAFFAELE CENTRO FOND filed Critical SAN RAFFAELE CENTRO FOND
Publication of JP2000506835A publication Critical patent/JP2000506835A/ja
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP9530545A 1996-02-27 1997-02-14 治療用の修飾サイトカイン Pending JP2000506835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT96A000358 1996-02-27
IT96MI000358A IT1282692B1 (it) 1996-02-27 1996-02-27 Citochine modificate per l'uso in terapia
PCT/EP1997/000704 WO1997031655A2 (en) 1996-02-27 1997-02-14 Modified cytokines for therapeutic use

Publications (1)

Publication Number Publication Date
JP2000506835A true JP2000506835A (ja) 2000-06-06

Family

ID=11373397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9530545A Pending JP2000506835A (ja) 1996-02-27 1997-02-14 治療用の修飾サイトカイン

Country Status (6)

Country Link
EP (1) EP0885015A2 (enExample)
JP (1) JP2000506835A (enExample)
AU (1) AU1769497A (enExample)
CA (1) CA2247308A1 (enExample)
IT (1) IT1282692B1 (enExample)
WO (1) WO1997031655A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016175916A (ja) * 2011-04-29 2016-10-06 ロシュ グリクアート アーゲー 新規なイムノコンジュゲート

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012554A1 (fr) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
FR2783528A1 (fr) * 1998-08-28 2000-03-24 Commissariat Energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
AU2009207287B2 (en) * 2008-01-25 2014-09-11 Gavish-Galilee Bio Applications Ltd Targeting of innate immune response to tumor site
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
JPH09506594A (ja) * 1993-12-07 1997-06-30 ネオルクス コーポレーション プレターゲティング方法及び化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016175916A (ja) * 2011-04-29 2016-10-06 ロシュ グリクアート アーゲー 新規なイムノコンジュゲート

Also Published As

Publication number Publication date
ITMI960358A0 (enExample) 1996-02-27
CA2247308A1 (en) 1997-09-04
AU1769497A (en) 1997-09-16
ITMI960358A1 (it) 1997-08-27
IT1282692B1 (it) 1998-03-31
WO1997031655A2 (en) 1997-09-04
EP0885015A2 (en) 1998-12-23
WO1997031655A3 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
JP6807132B2 (ja) 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途
Larsen et al. Albumin-based drug delivery: harnessing nature to cure disease
JPH09508141A (ja) ビタミンｂ▲下１２▼とタンパク質との複合体
KR100873593B1 (ko) 핵산 함유 복합체
US20130231287A1 (en) Pegylated albumin polymers and uses thereof
Xi et al. Liver targeting of interferon through pullulan conjugation
JPH10502334A (ja) 受容体調節剤およびこれに関連した方法
CZ308395A3 (en) Complex for b12 vitamin reception, process of its preparation, compositions containing thereof and its use
KR20030096356A (ko) 결합된 아포리포단백질 ｅ를 가지며 단백질로 제조된혈관-뇌 장벽 침투용 나노 입자 및 이들의 제조방법
JPH08510262A (ja) Ｇｃｓｆ及びｅｐｏ用ビタミンｂ▲下１▼▲下２▼介在経口デリバリーシステム
JPH07508004A (ja) プロテイノイド担体並びにその製造方法および使用方法
EP0885015A2 (en) Modified cytokines for therapeutic use
JP2009215319A (ja) コロイド状金属組成物および方法
JPH0889278A (ja) 遺伝子導入用修飾蛋白質及びその製法
EP2080804A1 (en) Modified cytokines for use in cancer therapy
JP2022514241A (ja) ミトコンドリア病を標的とするアナログ
Nie et al. A STING agonist-loaded bispecific nanobioconjugate modulates macrophage immune responses to enhance antitumor immunotherapy
JP2002003398A (ja) 徐放製剤、その製造法及びワクチン
WO2002085399A1 (fr) Preparations contenant un peptide
US20030103934A1 (en) Drugs having long-term retention in target tissue
HK1243000A1 (zh) 用於增强PPARγ表现及核转位之化合物及其医疗用途
US20130295052A1 (en) Novel conjugates for targeted drug delivery
WO1999065529A1 (en) Nucleic acid-cobalamin complexes and their use in gene therapy
EP0476408A1 (en) Chemical conjugation of morpholino anthracyclines to antibodies
Jarvinen et al. Systemically administered, target-specific therapeutic recombinant proteins and nanoparticles for regenerative medicine